RxDoctor Payments Data

Felice Egli, NP

Acute Care · Rochester, NYNPI 1114540358

Payments from drug & device makers

$2,654in general payments, 2019–2025

Across 111 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$430
  • Amgen$385
  • Kiniksa Pharmaceuticals, Ltd.$275
  • Cvrx, Inc.$247
  • Novartis$240
  • AstraZeneca$213
  • plus $865 from 11 others

What the payments were for

  • Food & beverage$2,47993%
  • Education$1767%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,654 in reported general payments places this provider in the 90th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$11,173
Medicare patients
111
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$280,452
EntrestoSacubitril/Valsartan141$189,803
FarxigaDapagliflozin Propanediol98$107,481
JardianceEmpagliflozin81$99,156
BrilintaTicagrelor36$40,052
XareltoRivaroxaban23$35,117
Repatha SureclickEvolocumab21$23,813
Praluent PenAlirocumab27$17,712
VascepaIcosapent Ethyl12$6,459
Metoprolol Succinate352$6,453
Atorvastatin Calcium367$5,612
Ezetimibe116$3,157
Rosuvastatin Calcium136$2,285
Carvedilol213$2,238
Diltiazem 12hr ErDiltiazem Hcl13$2,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$240$189,803141 claims
AstraZenecaFarxiga, Brilinta$213$147,533134 claims
Boehringer IngelheimJardiance$151$99,15681 claims
Johnson & JohnsonXarelto$75$35,11723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 980 acute care providers in New York.

Other acute care in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →